Diana Containerships Inc. (NASDAQ:DCIX) is on recovery track with 27.48% gain from a 1-year low price of $1.31. The company added 7.74% to attain the price of $1.67 on 05/17/2018. Throughout the recent session, the prices were hovering between $1.63 and $2.04. These shares are 268.86% off its target price of $6.16 and the current market capitalization stands at $13.09M. The recent change has given its price a 3.03% lead over SMA 50 and -99.95% deficit over its 52-week high. The stock witnessed 9.87% gains, -43.2% declines and -75.94% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found DCIX’s volatility during a week at 13.85% and during a month it has been found around 11.44%.Diana Containerships Inc. 13F Filings
At the end of 03/31/2018 reporting period, 5 institutional holders increased their position in Diana Containerships Inc. (NASDAQ:DCIX) by some 230,650 shares, 4 decreased positions by 32,109 and held positions by -21,564. That puts total institutional holdings at 241,195 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 230,650 shares while 2 institutional investors sold out their entire positions totaling 16,240 shares.
Multiple company employees have indulged in significant insider trading. Diana Containerships Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Former 10% owne Peter Gyllenhammar Ab has sold 50,000 shares of Diana Containerships Inc. (DCIX) in trading session dated Jul. 26, 2017. These shares are worth $80,500 and were traded at $1.61 each. The SEC filing shows that Peter Gyllenhammar Ab performed a sale of 4,286 shares. The Former 10% owne disposed these shares by way of transaction on Jul. 25, 2017. The company’s shares were given away at $26.46 per share worth to an income of some $113,408 on account of Peter Gyllenhammar Ab.
Turning to Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), its shares were trading at $18.08 a retreat of $-0.46, on the trading floor. The stock, after opening at $18.56, touched a high of $18.64 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.5. Ironwood Pharmaceuticals, Inc. has 3 buy ratings, 4 holds and 0 sells even after the stock tumbled -9.33% from its high of $19.94 to a $2.6 billion market value through last close.
The company’s consensus rating on Reuter’s scale slipped from 2.75 to 2.42 during a month. Analysts set a 12-month price target of $18.42 a share. The target implies a 1.88% spike from where the shares are currently trading. Also, the current price highlights a discount of 38.27% to analysts’ high consensus price target.Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Intraday Trading
The counter witnessed a trading volume of 1.39 million shares versus an average volume of 1.38 million shares during last trading session. Its last month’s stock price volatility remained 3.79% which for the week approaches 4.99%. The lowest price the stock reached in the last trading day was $17.81 and compares with the $12.89 52-week low. The stock recovered 40.26% since its low point and has performed 20.61% year-to-date.